Member Info for cadburyhill

F&C ASSET MANAGEMENT PLC Multiple Portfolios 6,552,505 -1,000,000 01/06/14 REG N-P 7.18% F&C ASSET MANAGEMENT PLC F&C UK Equity Fund 3,972,323 0 01/06/14 REG N-C 4.35% BANK OF MONTREAL /CAN/ n/a 4,152,852 0 18/07/14 RNS-MAJ N-P 4.55%

thanks for help here, alphapig. perhaps my bloomberg holdings data is out of date or wrong.

you need to include the bank of montreal holdings, too? but thanks....

Some very large prints again today.... We've got to be getting to the end of the overhang, surely? Fundamentally, I'm very pleased with progress and I think this management team has real integrity. But it's been tough for all of us to have to weather the institutional sell-down; a sell-down that has had nothing to do with SNG and everything to do with the mechanics of Bank of Montreal's purchase of F&C. I reckon there have been 17mn-odd shares that have had to find new homes since BofM effectively closed F&C's UK small cap business. Well, today we've probably shifted 7mn of that....Hope springs eternal.

Am pleased and reassured to see that the senior management are gearing themselves up into the upside potential of this stock, with 81p-ish as the floor for their ambitions (i.e. the current/strike price). I would have liked cash buying of stock by them rather than options but you can't have it all. If I were management and I had important strategic news to share, I'd want to get my options strike price sorted before the news flow release, not after. I think IKA shareholders can expect to hear news in the next month or two. perhaps it will be the final full sign-off on the pilot production line, perhaps it will be delivery of a prototype solid state battery unit to our European OEM? the risk/reward seems skewed in favour of buying more of this stock here, in my opinion. And to keep me 'honest', if we've heard nothing of significance by the early summer, then a full revisit of the investment case is probably in order.

Ok, it's time to buy OCN. At £9.00 you're getting the Wilson Sons Brazilian shipping business at a cyclical trough AND you get the investment book, valued at £4.00 a share, in for 'free'. The risks are: that the Petrobras corruption scandal affects Wilson Sons directly (it hasn't yet); that oil price has further to fall, and that Brazilian Real will continue to deval further as the Brazilian economy continues to falter. On the positive side, it's difficult to imagine sentiment being much worse with respect to Brazil, and its oil and gas industry in particular; the investment book should have performed well for yet another year (US equities are largest weighting); and everyone agrees this is a fine, well-run business with a fantastic long-term track-record. Buy.

Yes. you right. It's nice to let the stock do the work for you... Allied Minds is on a very good run, too... Imperial Innovations seems to be the laggard, perhaps held back by a disappointment at Circassia last month? But if you look at the historical charts, you'd buy IVO LN here. They tend to leap-frog each other....I do agree that the whole 'tech transfer' space seems to be coming into vogue.... 'future-proof' investing and all that..

i don't know the technical answer to your question. but if you think what goes on in your average hotel bedroom you have to hope and assume that the xeros process does a more than satisfactory job with respect to towel and sheet hygiene and therefore it's also suitable for 'heavy duty' use at home. as you know it's also currently being used by some US laundry franchises. one manager of a Boston laundry business stood up at the investor day to enthuse about the xeros process and what it did (or did not) do to customer shirts. Apparently, other conventional washes often shrink cheaper shirts, leading to complaints, etc. but this did not occur with xeros because of the lower temp. if xeros can clean my white shirt after a long, hot day at the office, i'm sure it can clean my kids sheets and clothes....

correct. great question. the healthcare market is huge. the same question was asked at the investor day in January. The answer given then was that there was currently no way around the need for hospitals to boil wash everything they launder but that the Xeros management were acutely aware of the massive opportunity in all corners of the healthcare/care-home market and there was some research underway to try to make the Xeros process relevant to that market (which I took to be management waffle for 'no, we can't sell into that area yet and we're not really sure when/if we'll be able to so')....one day. maybe!

Good morning to the merry band of ACT followers out there (I think we now number five?!). Have a look at the article in the weekend FT entitled 'Cyber Fast Lane Dreams Hit Hard Shoulder'. then join-up the dots to our ACT and their recent work for Ofcom. Could our guys be in the running for this project? And if they announced that they'd won the work/ or part of it, is the news already baked into the share price here? I just don't know...I suspect not but then I'm a very stale bull.

i tried so hard not to reply but just couldn't help it. if you'd written your comments when the stock price was at 220p and not around 25% lower then I might have congratulated you on your timing but this is a cheap shot. Of course, you could be right that this, as with all innovation companies, carries the real risk of hype and ultimate failure. But even on your numbers, 2x sales is a very cheap multiple for a growth stock and if I take your imagined gross? profit numbers and applied a haircut to get to some kind of ebitda measure then 10x ebitda ain't much for a growth stock either. conclusion: you really don't know what your talking about but you fancied trying to look smart by writing about an obvious risk in a stock that has already retraced aggressively. It was clear to us all that the chart was overly extended in the very short term. But what was encouraging was that the move higher came after a highly successful investor day in London with over 30 senior fund managers in attendance. This is a highly illiquid stock and doesn't take much to move it. The likes of Barnett and Woodford and IP Group and Reckitts (yep, they were early backers) aren't in this stock for a 10% gain. Their bet - and it is a bet, I accept - is that this is a potentially very disruptive technology that could be worth multiples of what it is now. I'd bet with them and against you. (and by the way, I've been in this stock for a long time so I'm not defending my bruised ego and a paper loss).

today's RNS re: the contract win is a reminder that last year management spent more time hiring and building out sales and marketing than they had done in previous years (they also had the distraction of listing their business on AIM). This year those sales and marketing people are up and running and, if the right people have been hired, we should start to hear about more contract wins in the coming months. I'm particularly excited about the US. One decent contract win there and suddenly ACT is noticed by a whole new group of potential clients (and investors). In my opinion, ACT has always been one of those stories where the outcome is binary. Either this company will become a key player in its field and be worth many multiples of what it's worth now, or it will fade quite quickly. I don't know what the probabilities are but one has to assume they're stacked against success (as with all on AIM). However, I think having some optionality/exposure to the upside scenario via a position that one can afford to lose makes a lot of sense. It's a firm that has a lot of intellectual integrity.

we just don't know, but I suspect it is the same trade. that's his skill: - deploying more capital than anyone else in situations where others have walked away or stopped caring. you can call all the shots when you trade in this way. sure, you need an end-game/exit but if you're well-resourced, patient and smart you can generate some stunning returns...he has done it time and again.

Richard Griffiths s a specialist investor in distressed/turn-around situations on AIM. He has been active for many years and he has a very successful track-record. He has been a good holder of OXA for a while. Today's RNS suggests he's upping his exposure. History suggests that others would be wise to follow where he leads...

yes, good luck to Opti. as I re-read my comments on Opti, I accept that they're hardly generous. truth be told, I've only had a cursory look at it...we can all benefit as the theme matures.

These guys haven't put a foot wrong so far... Another stunning RNS today and still the thundering herd takes no notice of it. That gives me a lot more confidence that there's plenty more to go for here. I note that OPTI LN, a similar play on the same microbiome theme but without the intellectual property to underpin it, has been heavily tipped as a star performer this year.

i added a wee bit in the last few days. I'm 95% convinced that the stock price reflects redemption/sell pressure from a couple of institutions and this has created an arbitrage opportunity for the patient. I'll buy some more when/if we get the positive price momentum which suggests the sell pressure is finally over and normal service can resume. this company is obviously high risk but it's in a really good place in terms of the science, funding and its partnering agreements.

let's hope it goes the way of Allied Minds, which listed earlier in the year and has been a fantastic buy.

I suspect that the problem here is an overhang via F&C (who were bought by Bank of Montreal and who I'm pretty sure have been a seller of other UK micro cap stocks close to my heart for the last few months). I also suspect Standard Life to be a seller of UK aim/small cap too because of redemptions at Nimmo's once hyper-popular UK small cap fund. But I have no evidence for that assertion with respect to SNG. Bottom-line is that this stock can go nowhere until the/se overhang/s is/are cleared. This may take a few months unless another institution or two come in to make use of a liquidity event to build a position. Once the overhang is eventually cleared, the stock will pop back up to fairish value, which I guess is around 50/60/70p. That's how I'm viewing things anyhow. To summarise: I'm frustrated but think we just need to be patient (which is the story of my life on AIM, of course)...

Agreed. This is an important change of equity ownership which leaves TRX really well positioned for future growth. We've shifted a considerable proportion of equity from a very early-stage, high-risk, essentially, private individual investor in the shape of Griffiths, to a proper institutional one, albeit with woodford's higher than average risk tolerance for smaller growth companies. Griffiths is to be congratulated in identifying and backing TRX when he did. He has made a many multiples return on his investment and deserves it. Woodford clearly sees this as a longer term winner and can be a source of capital for TRX when/if required. I think Odell is one of the most impressive CEOs I've seen for a long time. As an aside, note that all the specialist event money in London/NY is betting that Smith & Nephew will be taken out imminently. TRX, as a medtech play, clearly fits as a target for a US corporate at some point in the future, particularly given its US product / sales focus. Medtech is very prone to M&A historically.